The predicted allosteric binding of silodosin and acenocoumarol, based on molecular docking, may be contextualized by comparison with known EGFR allosteric inhibitors such as EAI045 and JBJ-09-063.41 These benchmark molecules have shown selective efficacy against EGFR mutations through distinct allosteric mechanisms.11 Although experimental validation for our compounds is pending, their predicted binding at similar pockets suggests a preliminary but promising avenue for future NSCLC therapeutics. Here, EGFR is linked to non-small cell lung carcinoma.